Class / Patent application number | Description | Number of patent applications / Date published |
424257100 | Escherichia (e.g., Escherichia coli, etc.) | 30 |
20080213317 | AVIAN E. COLI VACCINE FOR PROTECTION AGAINST COLIBACILLOSIS - A genetic deletion mutant live | 09-04-2008 |
20080286310 | Live Attenuated Bacterial Vaccine to Reduce or Inhibit Carriage and Shedding of Enterohemorrhagic Escherichia Coli in Cattle - The invention provides live, attenuated enterohemorrhagic | 11-20-2008 |
20090068230 | ENTEROHEMORRHAGIC ESCHERICHIA COLI VACCINE - Compositions and methods for stimulating an immune response against a secreted enterohemorragic | 03-12-2009 |
20090081257 | Hydrogenase deficient bacterial strains - The present disclosure describes pathogenic bacteria that have been modified to be deficient in NiFe hydrogenase activity; compositions comprising such modified bacteria, and the use of such bacteria to protect animals from pathogenic enteric bacterial infections. | 03-26-2009 |
20090081258 | KENNEL COUGH VACCINE - Improved, low cost vaccines for administration to living subjects such as mammals and birds are provided, which include killed recombinantly modified microorganisms (whole cell recombinant bacterin vaccine), the latter including recombinant DNA encoding at least one protective protein (e.g., an antigenic protein) which has been expressed by the microorganisms prior to killing thereof. The protective protein(s) are operable to prevent or reduce the severity of a disease of the subject. The vaccine preparations of the invention do not require separation of the protective protein(s) from the host recombinant microorganism(s), thereby materially decreasing the complexity and cost of the vaccine formulations. A preferred vaccine against kennel cough includes recombinantly modified microorganisms which express protective antigens containing pertactin and filamentous hemagglutinin protein products. | 03-26-2009 |
20090123500 | ACTIVE IMMUNIZATION USING A SIDEROPHORE RECEPTOR PROTEIN - The invention provides a vaccine for immunizing poultry and other animals against infection by a gram-negative bacteria, and a method of immunizing an animal using the vaccine. The vaccine may contain purified siderophore receptor proteins derived from a single strain or species of gram-negative bacteria or other organism, which are cross-reactive with siderophores produced by two or more strains, species or genera of gram-negative bacteria. The invention further provides a process for isolating and purifying the siderophore receptor proteins, and for preparing a vaccine containing the proteins. Also provided is a method for diagnosing gram-negative sepsis. | 05-14-2009 |
20090162402 | IMMUNIZING COMPOSITIONS AND METHODS OF USE - The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions. | 06-25-2009 |
20090232852 | USE OF OUTER MEMBRANE PROTEIN A (OMPA) IN TREATMENT/PREVENTION/DIAGNOSIS OF INFECTIONS CAUSED BY KLEBSIELLA PNEUMONIAE AND OTHER GRAM-NEGATIVE BACTERIA - The present invention provides a method for the treatment and/or prevention of bacterial infection caused by | 09-17-2009 |
20090297561 | Method for vaccination of poultry by bacteriophage lysate bacterin - The invention provides methods of generating phage lysate bacterins, as well as phage lysate bacterin compositions. The invention further encompasses methods of vaccination comprising administering phage lysate bacterin to an animal in need thereof. The invention further encompasses methods of reducing infection or colonization of poultry or poultry eggs using phage bacterin lysates. | 12-03-2009 |
20100003284 | Live attenuated aldolase-negative bacterial vaccine - A live attenuated bacterium of the genus | 01-07-2010 |
20100055135 | ENHANCIN OF HEPATITIS B VIRUS VACCINE AND ITS GENE - This invention relates to a HB vaccine enhancing protein, its gene, gene engineering method for expressing this protein, and the application of this method. The cDNA of this protein, which is screened out from human liver cDNA library, is sequenced and then cloned into prokaryotic or eukaryotic (animal or plant) cell for expression of protein coded by the cDNA (for example, cloning into prokaryotic expression carrier and expression in | 03-04-2010 |
20100136059 | HYBRID OPERON FOR EXPRESSION OF COLONIZATION FACTOR (CF) ANTIGENS OF ENTEROTOXIGENIC ESCHERICHIA COLI - A recombinant operon comprising a gene assembly wherein there are at least two structural genes coding for at least two major subunits of colonization factor antigens (CFs) associated with enterotoxigenic | 06-03-2010 |
20100150968 | Dna vectors - The present invention provides compositions and methods for expressing heterologous proteins useful in the treatment of cancer. | 06-17-2010 |
20100166802 | METHODS AND REAGENTS FOR DECREASING CLINICAL REACTION TO ALLERGY - The present invention provides methods and compositions for treating or preventing allergic reactions, particularly anaphylactic reactions. Methods of the present invention involve administering microorganisms to allergic subjects, where the microorganisms contain a recombinant version of the protein allergen. The recombinant version can be wild-type or may include mutations within IgE epitopes of the protein allergen. Preferably the compositions are administered rectally. Particularly preferred microorganisms are bacteria such as | 07-01-2010 |
20100255036 | ATTENUATED FNR DEFICIENT ENTEROBACTERIA - The invention provides an attenuated enterobacterium comprising an attenuating mutation in the fnr gene, and optionally further comprising a heterologous nucleic acid encoding a foreign antigen. Also provided are pharmaceutical formulations comprising the attenuated enterobacteria of the invention. Further disclosed are methods of inducing an immune response in a subject by administration of an immunogenically effective amount of an attenuated enterobacterium or pharmaceutical formulation of the invention. | 10-07-2010 |
20110206733 | Immunizing Compositions and Methods of Use - The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions. | 08-25-2011 |
20120058146 | IMMUNOGENS FROM UROPATHOGENIC ESCHERICHIA COLI - Disclosed herein are various genes that can be included in immunogenic compositions specific for pathogenic | 03-08-2012 |
20120093869 | LIVE-ATTENUATED COMPOSITIONS FOR BACTERIAL INFECTIONS - The present invention relates to compositions and methods for disease treatment and prevention through administration of a live attenuated composition. In particular, the present invention provides compositions and methods for the treatment and prevention of urinary tract infection by administration of a live attenuated compositions lacking O-antigen ligase activity. | 04-19-2012 |
20120093870 | ATTENUATED ENTEROHEMORRHAGIC E.COLI-BASED VACCINE VECTOR AND METHODS RELATING THERETO - An attenuated enterohemorrhagic | 04-19-2012 |
20130177593 | PERSONALIZED SITE-SPECIFIC IMMUNOMODULATION - The invention provides methods of treating inflammation in a specific organ or tissue of an individual. The method involves determining whether the individual has previously been infected with at least one pathogen that is pathogenic in the specific organ or tissue; and administering to the individual an anti-inflammatory composition comprising antigenic determinants, the antigenic determinants selected or formulated so that together they are specific for the at least one pathogen. The pathogen may be an endogenous or exogenous pathogen, and may further be a bacterial pathogen, a viral pathogen, a fungal pathogen, a protozoan pathogen, or a helminth pathogen. | 07-11-2013 |
20130251748 | USE OF OUTER MEMBRANE PORIN K36 PROTEIN (OMPK36) IN TREATMENT/PREVENTION/DIAGNOSIS OF ENTEROBACTERIACEAE INFECTION - The present invention relates a method for vaccinating a mammal to produce an antibody against Enterobacteriaceae infection caused by | 09-26-2013 |
20130280301 | Non-Natural Amino Acid Replication-Dependent Microorganisms and Vaccines - Compositions and methods of producing vaccines, including methods wherein whole organism vaccines are provided with limited replication abilities, thereby increasing vaccine safety and efficacy, through the use of non-natural, unnatural, or non-naturally encoded amino acids. | 10-24-2013 |
20130337012 | Tissue Targeted Antigenic Activation of the Immune Response to Treat Cancers - The invention provides in part methods for treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The compositions may for example include killed or attenuated microbial pathogens, such as whole killed bacterial cells, and may be administered at sites distant from the cancer, for example the skin. In selected embodiments, the invention provides methods for treating a cancer situated in the colon, using formulations of | 12-19-2013 |
20140010844 | Tissue Targeted Antigenic Activation of the Immune Response to Treat Cancers - The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. The formulations of the invention thereby facilitate activation of an immune response to a cancer in a particular tissue or organ. The compositions may for example include killed or attenuated microbial pathogens, such as whole killed bacterial cells, and may be administered at sites distant from the cancer, for example the skin. In some embodiments, microbial species of endogenous flora that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions. In alternative embodiments, exogenous microbial pathogens that are known to cause infection in the relevant organ or tissue may be used in the formulation of the antigenic compositions. The administration of the immunogenic compositions may be repeated relatively frequently over a relatively long period of time. In embodiments for intradermal or subcutaneous injection, dosages may be adjusted so that injections reproduce a consistent, visible, delayed inflammatory immune reaction at the successive site or sites of administration. | 01-09-2014 |
20140065188 | Enterohemorrhagic Escherichia Coli Vaccine - Compositions and methods for stimulating an immune response against a secreted enterohemorragic | 03-06-2014 |
20140178436 | METHOD FOR INCREASING ETEC CS6 ANTIGEN PRESENTATION ON CELL SURFACE AND PRODUCTS OBTAINABLE THEREOF - A method for increasing the presentation of ETEC CS6 antigen on cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETEC. Cells and vaccines obtainable by the above methods. | 06-26-2014 |
20150024005 | AUGMENTATION OF TITER FOR VACCINATION IN ANIMALS - The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer of antibodies to the vaccine. | 01-22-2015 |
20150320850 | VACCINE FOR PROTECTION AGAINST ETEC-INDUCED DIARRHEA COMPRISING DMLT - An oral vaccine for immunization against ETEC-induced diarrhea, comprising inactivated | 11-12-2015 |
20160045584 | CAMPYLOBACTER VACCINE - The present application provides a vaccine composition comprising: bacteria engineered to express at least one N-glycan of | 02-18-2016 |
20160199474 | INCAPACITATED WHOLE-CELL IMMUNOGENIC BACTERIAL COMPOSITIONS PRODUCED BY RECOMBINANT EXPRESSION | 07-14-2016 |